Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genmab US, Inc., and MorphoSys US, Inc.
Cancer Summaries and Commentaries: Report from Atlanta on Advances in the Treatment of DLBCL
Release Date: December 23, 2021
Expiration Date: December 23, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Genmab US, Inc., and MorphoSys US, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the study design and rationale of recent clinical trials evaluating targeted and cellular therapies for the treatment of DLBCL in different settings
- Assess practice-changing results from recent trials that have evaluated targeted and cellular therapies for the treatment of DLBCL
- Evaluate recent clinical trial evidence on targeted and cellular therapies within the context of evolving treatment paradigms for patients with DLBCL
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty
Division head ad interim, Division of Cancer Medicine
Chair & Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consultant: AbbVie, Bayer Healthcare, BeiGene, Celgene Corp, Denovo Biopharma, Epizyme, Genentech/Roche, Genmab, Gilead Sciences, Karyopharm, Pharmacyclics/Janssen Pharmaceuticals, SeaGen, Spectrum Pharmaceuticals; Grant/Research Support: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceuticals, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda Oncology, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research.
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Vancouver, Canada
Disclosures: Grant/Research Support: Roche; Consultant: Roche/Genentech, Incyte, AbbVie, Kite.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
